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Jungmin Kim and Yongsoon Park*Abstract
Background: It has been suggested that Sorghum, a rich source of phytochemicals, has a hypoglycemic effect, but
the mechanism is unknown. We investigated the effects of oral administration of sorghum extract (SE) on hepatic
gluconeogenesis and the glucose uptake of muscle in streptozotocin-induced diabetic rats for six weeks.
Methods: Male Wistar rats were divided in five groups (n=5 per group): normal control (NC), rats with STZ-induced
diabetic mellitus (DM), diabetic rats administrated 0.4 g/kg body weight of SE (DM-SE 0.4) and 0.6 g/kg body
weight of SE (DM-SE 0.6), and diabetic rats administrated 0.7 mg/kg body weight of glibenclamide (DM-G).
Results: Administration of SE and G reduced the concentration of triglycerides, total and LDL-cholesterol and
glucose, and the area under the curve of glucose during intraperitoneal glucose tolerance tests down to the levels
observed in non-diabetic rats. In addition, administration of 0.4 and 0.6 g/kg SE and 0.7 mg/kg glibenclamide (G)
significantly reduced the expression of phosphoenolpyruvate carboxykinase and the phosphor-p38/p38 ratio, while
increased phosphor adenosine monophosphate activated protein kinase (AMPK)/AMPK ratio, but the glucose
transporter 4 translocation and the phosphor-Akt/Akt ratio was significantly increased only by administration of G.
Conclusions: These results indicate that the hypoglycemic effect of SE was related to hepatic gluconeogenesis but
not the glucose uptake of skeletal muscle, and the effect was similar to that of anti-diabetic medication.
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Diabetes mellitus is a metabolic disease characterized by
chronic hyperglycemia [1] caused by increased hepatic
glucose production [2] or abnormal glucose use in skel-
etal muscle [3]. Phosphoenolpyruvate carboxykinase
(PEPCK), an important enzyme of gluconeogenesis, is
regulated by the adenosine monophosphate activated
protein kinase (AMPK) or p38 pathways [4,5]. Addition-
ally, glucose transporter (GLUT4) is a rate-limiting fac-
tor for glucose uptake in skeletal muscle, and Akt
(protein kinase B) is a central mediator of insulin-
induced GLUT4 translocation from cytosol to mem-
brane [6]. These protein expressions have been shown to
be associated with the pathogenesis in streptozotocin
(STZ)-induced diabetic rats [7-9].* Correspondence: yongsoon@hanyang.ac.kr
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reproduction in any medium, provided the orBecause of the adverse effects of diabetic medication
such as the pain by injection, insulin resistance or
hypoglycemic symptoms, there is increasing investiga-
tion into the use of herbs and plants for the treatment
of diabetic mellitus. Sorghum bicolor L. Monech is the
fifth most important cereal crop worldwide, both in
terms of planted area and metric tons harvested [10].
Sorghum flour is a rich source of phytochemicals, tan-
nins, phenolic acids, anthocyanins, phytosterols, and
policosanols, and these bioactive components have been
reported to have antioxidant [11,12], anti-carcinogenic
[13], and cholesterol-lowering properties [14,15]. Previ-
ously, sorghum extracts have been shown to have
hypoglycemic activity in STZ-induced diabetic rats [16];
however, the mechanism is unclear. Thus, we investi-
gated the hypothesis that sorghum extract (SE) has
hypoglycemic effects through inhibition of hepaticl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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uptake in skeletal muscle in STZ-induced diabetic rats.
Methods
Animals and diet
Protocol approved by the Institutional Animal Care and
Use Committee of Hanyang University was used for all
animal experiments (HY-IACUC-11-059). Six week old
male Wistar rats (Orient, Gyeonggi-do, Korea) were
housed in individual ventilated in an air-conditioned
room maintained at 22±2°C with a 12 h light–dark cycle.
After one week of acclimatization, twenty rats were
intraperitonially injected with STZ (70 mg/kg body
weight in 0.05 M citrate buffer; Sigma Co, St. Louis,
MO, USA) once, and then blood glucose concentration
was measured to confirm the development of diabetes
mellitus. After 3 days of STZ injection, twenty STZ-
induced diabetic rats and five normal rats without STX
injection were fed with an AIN-93M diet (Research
Diets, New Brunswick, NJ, USA) and water ad libitum
for 6 weeks, and the body weight and food intake were
recorded every week.
Sorghum (Sorghum bicolor L. Moench cv. Hwang-
geumchal-susu) was grown at the Department of Func-
tional Crops, National Institute of Crop Science, Rural
Development Administration, Milyang, Korea during the
2010 growing season. Voucher herbarium specimens
were deposited with the reference number (KNICS-579)
in the Herbarium of the Department of Functional
Crops. The botanical identification was made by Dr. Ill-
Min Chung of Konkuk University [16]. Sorghum was
finely ground using a Pin-type Mill (DK-201, Sejung
Tech, Daegu, Korea) and extracted using 80% fermented
ethanol at room temperature for 24 h while shaking
(WiseCube WIS-RL010, Daihan Scientific Co., Ltd.,
Seoul, Korea). The extracts were centrifuged at 5,000 g
for 30 min and the supernatants were filtered through
Advantec 2 filter paper (Advantec Toyo Kaisha Ltd.,
Tokyo, Japan). The filtrates were evaporated using a ro-
tary evaporator (Eyela N-1000, Tokyo Rikakikai Co.,
Tokyo, Japan) at 40°C, and then freeze-dried in vacuum
(FDT-8612, OPERON, Kimpo, Korea). The dried extract
was stored at −20°C.
During a six-week period of diet, normal control rats
(NC) were orally administrated 0.1 mL of saline, and
twenty STZ-induced diabetic rats were randomly divided
into four groups that orally administrated either 0.1 mL
of saline (DM) or 0.1 mL of saline with a 0.4 g/kg body
weight of SE (DM-SE 0.4), 0.6 g/kg body weight of SE
(DM-SE 0.6) or 0.7 mg/ kg body weight of glibenclamide
(DM-G) using gavage (n = 5 per group).
Intraperitoneal glucose tolerance tests (IPGTT) were
performed by intraperitoneal injection of 25% glucose (2
g/kg body weight) on the last day of the experiment afteran overnight fast. Blood samples were collected from the
tail vein at 30, 60, and 120 min after injection.
At the end of the experimental period, all rats were
anesthetized with an intraperitoneal injection of tileta-
mine (25 mg/kg), zolazepam (25 mg/kg), and xylazine
(10 mg/kg) after overnight fasting. Blood was collected
into SST tubes (BD Vacutainer, Franklin Lakes, NJ,
USA) and centrifuged at 3000 g for 15 min (HA 1000–3,
Hanil Sciences Industrial CO. Ltd., Incheon, Korea).
Organs and adipose tissues were harvested, rinsed with
saline and then weighed [17]. Serum and tissue samples
were stored at −80°C.
Biochemical assays
Glucose concentration during IPGTT was determined
with AccuCheck (Roche Diagnostics, Indianapolis, IN,
USA). The values of the area under the glucose time
curve (AUC) were calculated using the glucose levels at
each time point during IPGTT. The serum levels of tri-
glycerides, total- and HDL-cholesterol, glucose, glutamic
oxaloacetic transaminase (GOT), and glutamic pyruvic
transaminase (GPT) were determined using a commer-
cially available kit (Asan Pharm., Hwaseong, Korea) with
a spectrophotometer (DU 600, Beckman Coulter, Inc.,
Indianapolis, IN, USA). LDL-cholesterol concentration
was calculated using the Friedwald formula. The serum
insulin level was determined using an ultra-sensitive rat
insulin enzyme linked immunosorbent assay kit (Crystal
Chem, Downers Grove, IL, USA) with a microplate
reader (iMark, Bio-Rad Laboratories, Hercules, CA,
USA).
Western blotting
Liver and skeletal muscles were homogenized in a 0.8 ml
ice-cold lysis buffer (20 mM HEPES, 0.25 M sucrose,
0.5 mM EDTA, 2 mM dithiothreitol, 1 mM PMSF,
10 μg/mL leupeptin, 10 μg/mL aprotinin, and 1mM
Na3VO4, pH 7.5). The homogenates were centrifuged at
10,000 g for 15 min at 4°C, and the supernatant was cen-
trifuged at 20,000 g for 1 h at 4°C to obtain cytosolic
fraction. For the membrane fraction of skeletal muscle,
the pellets were re-suspended in 250 μl of lysis buffer
and 1% (v/v) triton X-100, incubated on ice for 30 min,
and centrifuged at 200,000 g for 30 min at 4°C. The pro-
tein concentrations were determined using a Bradford
assay with bovine serum albumin (Bio-Rad, Hercules,
CA, USA) as the standard. Equal amounts of protein
(30μg) from liver or skeletal muscle was separated on 8%
SDS-PAGE and transferred to a polyvinylidine fluoride
membrane (0.45 μm, Immobilon-P transfer membrane,
Millipore, USA). After blocking, the membranes were
incubated overnight with a primary antibody for PEPCK
(1:1,000, Cell Signaling Technology, Beverly, MA, USA),
p38 (1:1,000, Cell Signaling Technology, Beverly, MA,
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Beverly, MA, USA), AMPK (1:1,000, Cell Signaling
Technology, Beverly, MA, USA), phospho AMPK (1:500,
Cell Signaling Technology, Beverly, MA, USA), GLUT4
(1:2000, abCam, Cambridge, UK), Akt (1:1,000, Cell Sig-
naling Technology, Beverly, MA, USA), or phospho-Akt
(1:500, Cell Signaling Technology, Beverly, MA, USA) in
Tris-buffered saline with Tween 20 (TBST) containing
5% nonfat milk at 4°C. After washing in TBST, the mem-
branes were incubated with horseradish peroxidase con-
jugated goat anti-rabbit or mouse IgG (1:5,000, Cell
Signaling Technology, Beverly, MA, USA) for 1 h. The
immunoreactive signals were developed using an
enhanced chemiluminescence kit (GE Healthcare Life
Sciences, Piscataway, NJ, USA) and exposed to Kodak
film. The relative and normalized protein expression
was calculated by β-action (1:1,000, BD Transduction
Laboratories, NJ, USA).
Statistical analysis
All data are expressed as the mean ± standard error of
the mean (SEM). Statistical differences among the
groups were calculated by the analysis of variance
(ANOVA) followed by Duncan’s multiple range test
(SPSS 18.0 version., Chicago, IL, USA). Differences with
p < 0.05 were considered significant.
Results
Food intake, body weight, and organ weights
Dietary intake, and weight of liver and kidney as per-
centage of body weight were significantly greater in all
DM groups than in the NC group, but body weight and
weight of retroperitoneal, epididymal and perirenal adi-
pose tissues were significantly lower in all DM groups
than in the NC group (Table 1). Among the DM groups,
there were no significant differences in dietary intake,
body weight and weight of adipose tissue, liver and
kidney.Table 1 Dietary intake, body weight and various organ weigh
NC DM
Dietary intake (g/day) 22.10±0.23a 25.94±1.30b
Initial body weight (g/day) 246.20±6.76a 208.60±7.79b
Final body weight (g/day) 491.40±9.01a 375.40±43.17b
Liver (mg/g body weight) 11.52±0.57a 11.40±0.66b
kidney (mg/g body weight) 2.73±0.10a 2.91±0.07b
Retroperitoneal fat (g) 12.11±1.07a 8.52±0.62b
Epididymal fat (g) 11.82±0.81a 8.97±0.27b
Perirenal fat (g) 0.99±0.21 0.93±0.15
Values are expressed as the mean ± SEM (n = 5); NC, normal control rats administra
with diabetes mellitus administrated 0.4 g/kg body weight of sorghum extract; DM-
sorghum extract; DM-G, rats with diabetes mellitus administrated 0.7 mg/kg body w
significantly different at p < 0.05 using ANOVA with Duncan’s multiple range test.Levels of glucose, insulin lipid profiles, and liver function
Serum concentrations of triglycerides, and total- and
LDL-cholesterol were significantly lower in the DM-SE
0.4 , DM-SE 0.6, DM-G, and NC groups than the DM
group, while HDL-cholesterol level was significantly
lower in DM-G than the other DM and NC groups
(Table 2). There were no significant differences in serum
levels of glutamic oxaloacetic transaminase and glutamic
pyruvic transaminase, suggesting that SE had no harmful
effect on liver function. Serum glucose concentration
and AUC during IPGTT were significantly lower in DM-
SE 0.6 and DM-G than in DM, but not DM-SE 0.4
(Table 2). Serum insulin level in DM-G was significantly
increased up to that of NC, but SE had no significant ef-
fect on insulin concentration. Blood glucose levels
reached a peak at 30 min during IPGTT (Figure 1), and
the peak concentrations of glucose were significantly
lower in DM-SE 0.4 and DM-SE 0.6 than DM, but
higher than NC and DM-G (Figure 1).Protein expression in liver and muscle
The expression of PEPCK and the phosphor-p38/p38
ratio were significantly lower, while the phospho-AMPK/
AMPK ratio was significantly higher in NC, DM-SE 0.4,
DM-SE 0.6, and DM-G than in DM, suggesting that SE
and G decreased hepatic gluconeogenesis (Figure 2).
Phosphorylation of Akt and GLUT4 translocation was
significantly decreased in DM as compared with NC, but
SE had no significant effect (Figure 3). On the other
hand, GLUT4 translocation was significantly increased
by the administration of G, suggesting that G reduced
blood glucose levels by both reducing hepatic gluconeo-
genesis and increasing glucose uptake by muscle.
Discussion
The present study demonstrates that oral administration
of SE significantly reduces blood glucose concentrationts









ted saline; DM, rats with diabetes mellitus administrated saline; DM-SE 0.4, rats
SE 0.6, rats with diabetes mellitus administrated 0.6 g/kg body weight of
eight of glibenclamide. The values in the rows with different letters are
Table 2 Lipid profiles, liver function, and levels of glucose and insulin in serum
NC DM DM-SE 0.4 DM-SE 0.6 DM-G
Triglycerides (mmol/L) 0.92±0.15a 1.86±0.13b 0.75±0.13a 0.68±0.12a 0.89±0.02a
Total cholesterol (mmol/L) 2.01±0.10a 2.70±0.19b 1.81±0.05a 1.81±0.06a 2.14±0.10a
HDL-cholesterol (mmol/L) 1.20±0.04a 1.33±0.02a 1.28±0.02a 1.34±0.06a 1.02±0.09b
LDL-cholesterol (mmol/L) 0.73±0.03a 1.25±0.07b 0.82±0.07a 0.72±0.04a 0.88±0.05a
Glutamic oxaloacetic transaminase (IU/L) 42.81±1.19 46.02±2.92 42.94±2.05 44.26±0.73 45.03±1.52
Glutamic pyruvic transaminase (IU/L) 14.54±3.45 12.72±1.20 13.78±1.94 10.17±0.73 9.68±1.96
Glucose (mmol/L) 1.18±0.06a 1.67±0.12c 1.51±0.07bc 1.29±0.02b 1.21±0.12a
Insulin (pmol/L) 3.73±0.27a 1.25±0.20b 1.64±0.26ab 1.91±0.11ab 3.69±1.46a
AUC of glucose (mmol·min/L) 748.25±27.39a 1250.25±35.24c 881.20±39.61b 907.76±29.55b 781.39±23.36a
Values are expressed as mean ± SEM (n = 5); NC, normal control rats administrated saline; DM, rats with diabetes mellitus administrated saline; DM-SE 0.4, rats
with diabetes mellitus administrated 0.4 g/kg body weight of sorghum extract; DM-SE 0.6, rats with diabetes mellitus administrated 0.6 g/kg body weight of
sorghum extract; DM-G, rats with diabetes mellitus administrated 0.7 mg/kg body weight of glibenclamide; AUC, area under the curve during intraperitoneal
glucose tolerance tests. The values in the rows with different letters were significantly different at p < 0.05 using ANOVA with Duncan’s multiple range test.
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neogenesis through suppression of PEPCK and p38 ex-
pression and increases AMPK expression. However, SE
had no significant effect on glucose uptake by skeletal
muscle determined by GLUT4 translocation and Akt
phosphorylation, suggesting that the hypoglycemic
effects of SE may be related to an insulin independent
pathway.
These hypoglycemic effects were consistent with the
results of a recent study that found that SE rich tannins
at dosages of 0.25-0.5 g/kg of body weight significantly
decreased serum glucose concentration in STZ-induced
diabetic rats [16] and mice fed a high fat diet [18]. A
previous study showed that SE strongly inhibited in vitro
activities of α-glucosidase and α-amylase, targets for the
development of diabetic drugs [19]. Lakshmi et al. [20]Figure 1 Blood glucose levels during the intraperitoneal glucose tole
diabetes mellitus administrated saline; DM-SE 0.4, rats with diabetes mellitu
rats with diabetes mellitus administrated 0.6 g/kg body weight of sorghum
body weight of glibenclamide. The values are mean ± SEM (n = 5). Values
ANOVA with Duncan’s multiple range test.also reported that sorghum grain significantly reduced
the fasting glucose level and the AUC of glucose in type
2 diabetic patients. The SE used in the present study
was 0.4-0.6 g/kg of body weight, which was translated as
20–30 g of sorghum grain per kg of body weight for
human. Due to the low yield rate, it may not be achiev-
able to reduce blood glucose levels by consumption of
intact sorghum grain.
In the present study, administration of SE significantly
reduced the expression of PEPCK and phosphor-p38,
while increasing phosphor-AMPK. Expression of PEPCK
is an important factor responsible for hepatic gluconeo-
genesis [2,21], and has previously been shown to in-
crease in the liver of diabetic rats [7,8]. In addition, the
p38 pathway increased the expression of PEPCK
[8,22,23], but the p38-activated PEPCK signal pathwayrance tests. NC, normal control rats administrated saline; DM, rats with
s administrated 0.4 g/kg body weight of sorghum extract; DM-SE 0.6,
extract; DM-G, rats with diabetes mellitus administrated 0.7 mg/kg










Figure 2 Expression of phosphoenolpyruvate carboxykinase (PEPCK), adenosine monophosphate activated protein kinase (AMPK), and
p38. NC, normal control rats administrated saline; DM, rats with diabetes mellitus administrated saline; DM-SE 0.4, rats with diabetes mellitus
administrated 0.4 g/kg body weight of sorghum extract; DM-SE 0.6, rats with diabetes mellitus administrated 0.6 g/kg body weight of sorghum
extract; DM-G, rats with diabetes mellitus administrated 0.7 mg/kg body weight of glibenclamide. The values are mean ± SEM (n = 5). The values
with different superscripts are significantly different at p < 0.05 using ANOVA with Duncan’s multiple range test.







Figure 3 Expression of the glucose transporter (GLUT) 4 and Akt (protein kinase B). NC, normal control rats administrated saline; DM, rats
with diabetes mellitus administrated saline; DM-SE 0.4, rats with diabetes mellitus administrated 0.4 g/kg body weight of sorghum extract; DM-SE
0.6, rats with diabetes mellitus administrated 0.6 g/kg body weight of sorghum extract; DM-G, rats with diabetes mellitus administrated 0.7 mg/kg
body weight of glibenclamide. The values are mean ± SEM (n = 5). The values with different superscripts are significantly different at p < 0.05
using ANOVA with Duncan’s multiple range test.
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also been reported that the AMPK-α 2 catalytic subunit
is a key target for the regulation of hepatic glucose pro-
duction by adiponectin and leptin but not insulin, sug-
gesting that AMPK is regulated by a mechanism distinct
from insulin [7,25,26]. Since we observed that SE signifi-
cantly reduced blood glucose concentration but did not
significantly change insulin levels, these results indicate
that SE reduces hepatic gluconeogenesis through an in-
sulin independent pathway.
GLUT4 is the rate-limiting step for glucose uptake by
an insulin dependent pathway in skeletal muscle [27],
and GLUT4 translocation from cytosol to the plasma
membrane is regulated by Akt [9,28]. Previous studies
have observed that blood glucose levels increase with
reductions of insulin concentration in GLUT4 knockout
mice [29]. Additionally, Akt and GLUT4 translocation of
skeletal muscle was reduced in STZ-induced diabetic
rats [8] and impaired in diabetic patients [30]. Zhou
et al. [26] consistently reported that glucose uptake was
not induced by phosphorylation of Akt nor the expres-
sion and translocation of GLUT4 when insulin levels
were low. In the present study, administration of SE had
no significant effect on GLUT 4 translocation and the
phosphor-Akt/Akt ratio, suggesting that the hypogly-
cemic effect of SE was not related to glucose uptake by
skeletal muscle.
In this study, administration of SE also significantly
decreased the concentration of triglycerides as well as
total- and LDL-cholesterol. Previous studies have con-
sistently showed that SE decreases cholesterol levels by
reducing hepatic cholesterol synthesis and increasing
cholesterol excretion into feces [6,11]. Chung et al. [16]
also observed that SE markedly decreased the serum
concentration of total-cholesterol, suggesting that
HMG-CoA reductase might be responsible. Therefore,
these results indicate that SE may have beneficial bio-
active components that could exert blood lipid profiles
in humans [11], but whether SE has the ability to reduce
cholesterol synthesis through HMG-CoA reductase
in vivo warrants further investigation.
Our study had a few limitations. We did not measure
the active components in the 80% ethanol extract of sor-
ghum or determine whether the protein expression was
due to a change in mRNA levels. We also did not ob-
serve the dose dependency of SE. In conclusion, the oral
administration of SE significantly reduced blood glucose
concentration by inhibition of hepatic gluconeogenesis,
particularly via suppression of PEPCK and p38 expres-
sion, and increased AMPK expression in STZ-induced
diabetic rats.
Abbreviations
Akt: Protein kinase B; AMPK: Adenosine monophosphate activated protein
kinase; G: Glibenclamide; GLUT: Glucose transporter; p38: p38 mitogen-activated protein kinase; PEPCK: Phosphoenolpyruvate carboxykinase;
SE: Sorghum extract; STZ: Streptozotocin.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
JK conducted the research and wrote the manuscript. YP designed the
research and had primary responsibility for the final content. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by a grant from the Korea Research Foundation
funded by the Korea Rural Development Administration (PJ006983201005).
Received: 21 August 2012 Accepted: 20 November 2012
Published: 27 November 2012
References
1. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and
classification of diabetes in children and adolescents. Pediatr Diabetes
2009, 10:3–12.
2. Agius L: New hepatic targets for glycaemic control in diabetes. Best Pract
Res Clin Endocrinol Metab 2007, 21:587–605.
3. Standaert ML, Ortmeyer HK, Sajan MP, Kanoh Y, Bandyopadhyay G,
Hansen BC, Farese RV: Skeletal muscle insulin resistance in
obesity-associated type 2 diabetes in monkeys is linked to a defect
in insulin activation of protein kinase C-zeta/lambda/iota. Diabetes 2002,
51:2936–2943.
4. Cao W, Collins QF, Becker TC, Robidoux J, Lupo EG Jr, Lupo EG, Xiong Y,
Daniel KW, Floering L, Collins S: p38 Mitogen-activated protein kinase
plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem 2005,
280:42731–42737.
5. Pilkis SJ, Granner DK: Molecular physiology of the regulation of hepatic
gluconeogenesis and glycolysis. Annu Rev Physiol 1992, 54:885–909.
6. He A, Liu X, Liu L, Chang Y, Fang F: How many signals impinge on GLUT4
activation by insulin? Cell Signal 2007, 19:1–7.
7. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, Yang D, Liang H, Ye J, Weng J:
Berberine improves glucose metabolism in diabetic rats by inhibition of
hepatic gluconeogenesis. PLoS One 2011, 6:e16556–e16565.
8. Liu SH, Chang YH, Chiang MT: Chitosan reduces gluconeogenesis and
increases glucose uptake in skeletal muscle in streptozotocin-induced
diabetic rats. J Agric Food Chem 2010, 58:5795–5800.
9. Liu M, Wu K, Mao X, Wu Y, Ouyang J: Astragalus polysaccharide improves
insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in
skeletal muscle. J Ethnopharmacol 2010, 127:32–37.
10. Awika JM, Rooney LW: Sorghum phytochemicals and their potential
impact on human health. Phytochemistry 2004, 65:1199–1221.
11. Kim JS, Hyun TK, Kim MJ: Anti-oxidative activities of sorghum, foxtail
millet and proso millet extracts. Afr J Biotechnol 2010, 9:2683–2690.
12. Sikwese FE, Duodu KG: Antioxidant effect of a crude phenolic extract
from sorghum bran in sunflower oil in the presence of ferric ions.
Food Chem 2007, 104:324–331.
13. van Rensburg SJ: Epidemiologic and dietary evidence for a specific
nutritional predisposition to esophageal cancer. J Natl Cancer Inst 1981,
67:243–251.
14. Hoi JT, Weller CL, Schlegel VL, Cuppett SL, Lee JY, Carr TP: Sorghum
distillers dried grain lipid extract increases cholesterol excretion and
decreases plasma and liver cholesterol concentration in hamsters.
J Funct Foods 2009, 1:381–386.
15. Carr TP, Weller CL, Schlegel VL, Cuppett SL, Guderian DM Jr, Johnson KR:
Grain sorghum lipid extract reduces cholesterol absorption and plasma
non-HDL cholesterol concentration in hamsters. J Nutr 2005,
135:2236–2240.
16. Chung IM, Kim EH, Yeo MA, Kim SJ, Seo MC, Moon HI: Antidiabetic effects
of three Korean sorghum phenolic extracts in normal and
streptozotocin-induced diabetic rats. Food Res Int 2011, 44:127–132.
17. Remesar X, Fernández-López JA, Blay MT, Savall P, Salas A, Díaz-Silva M,
Esteve M, Grasa MM, Alemany M: Effect of oral oleoyl-estrone on adipose
tissue composition in male rats. Int J Obes Relat Metab Disord 2002,
26:1092–102.
Kim and Park Nutrition & Metabolism 2012, 9:106 Page 7 of 7
http://www.nutritionandmetabolism.com/content/9/1/10618. Park JH, Lee SH, Chung IM, Park Y: Sorghum extract exerts an anti-diabetic
effect through improvement of insulin sensitivity via PPAR-γ in mice
with high-fat diet. Nutr Res Pract 2012, 6:322–327.
19. Kim JS, Hyun TK, Kim MJ: The inhibitory effects of ethanol extracts from
sorghum, foxtail millet and proso millet on α-glucosidase and α-amylase
activities. Food Chem 2011, 124:1647–1651.
20. Lakshmi KB, Vimala V: Hypoglycemic effect of selected sorghum recipes.
Nutr Res 1996, 16:1651–1658.
21. Okamoto T, Kanemoto N, Ban T, Sudo T, Nagano K, Niki I: Establishment
and characterization of a novel method for evaluating gluconeogenesis
using hepatic cell lines, H4IIE and HepG2. Arch Biochem Biophys 2009,
491:46–52.
22. Qiao L, MacDougald OA, Shao J: CCAAT/enhancer-binding protein alpha
mediates induction of hepatic phosphoenolpyruvate carboxykinase by
p38 mitogen-activated protein kinase. J Biol Chem 2006, 281:24390–24397.
23. Cheong J, Coligan JE, Shuman JD: Activating transcription factor-2
regulates phosphoenolpyruvate carboxykinase transcription through a
stress-inducible mitogen-activated protein kinase pathway. J Biol Chem
1998, 273:22714–22718.
24. Berasi SP, Huard C, Li D, Shih HH, Zhong W, Paulsen JE, Brown EL,
Gimeno RE, Martinez RV: Inhibition of gluconeogenesis through
transcriptional activation of EGR1 and DUSP4 by AMP-activated
kinase. J Biol Chem 2006, 281:27167–27177.
25. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iqlesias MA, Pillot B,
Bado A, Tronche F, Mithieux G, Vaulont S, Burcelin R, Viollet B: Liver
adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a
key target for the control of hepatic glucose production by adiponectin
and leptin but not insulin. Endocrinology 2006, 147:2432–2441.
26. Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, Li F, Tang J, Chen M,
Chen J: Berberine stimulates glucose transport through a mechanism
distinct from insulin. Metabolism 2007, 56:405–412.
27. Dugani CB, Klip A: Glucose transporter 4: cycling, compartments and
controversies. EMBO Rep 2005, 6:1137–1142.
28. van Dam EM, Govers R, James DE: Akt activation is required at a late
stage of insulin-induced GLUT4 translocation to the plasma membrane.
Mol Endocrinol 2005, 19:1067–1077.
29. Kadowaki T: Insights into insulin resistance and type 2 diabetes from
knockout mouse models. J Clin Invest 2000, 106:459–465.
30. Kahn BB, Rosen AS, Bak JF, Andersen PH, Damsbo P, Lund S, Pedersen O:
Expression of GLUT1 and GLUT4 glucose transporters in skeletal muscle
of humans with insulin-dependent diabetes mellitus: regulatory effects
of metabolic factors. J Clin Endocrinol Metab 1992, 74:1101–1109.
doi:10.1186/1743-7075-9-106
Cite this article as: Kim and Park: Anti-diabetic effect of sorghum extract
on hepatic gluconeogenesis of streptozotocin-induced diabetic rats.
Nutrition & Metabolism 2012 9:106.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
